和田验孕纸一深一浅是什么意思(和田专科男科医院哪好呢) (今日更新中)

BEIJING, Sept. 14 (Xinhuanet) -- Facebook unveiled a new feature called "smart lists" on Tuesday, giving its users an easier way to share photos, posts and updates with smaller groups of friends.The new function, which commences on Wednesday, borrows from the success of the Circles feature of Google+, which allows users to categorize friends into groups.With the new feature, Facebook can automatically put your friends into groups, with the first four being work, school, family and city, based on the information of colleges, workplaces and geographic locations in users' profiles.The feature is optional to use, and the lists are customizable."This is really something we have been working on for four years," Facebook director of product management Blake Ross told AFP, adding "We think this is the way people will make lists going forward."In the meantime, the social networking site has also come up with "close friends" and "acquaintances" options.People can read the updates of their "close friends" more prominently in their news feed and just big news of their "acquaintances", according to Naomi Gleit, the director of product at Facebook who worked on the new feature.

WASHINGTON, Aug. 17 (Xinhua) -- Latest research shows that the Moon could be younger than previous estimates. The findings were published online Wednesday in the Nature journal.The prevailing theory of the Moon's origin is that it was created by a giant impact between a large planet-like object and the proto-Earth. The energy of this impact was sufficiently high that the Moon formed from melted material that was ejected into space. As the Moon cooled, this magma solidified into different mineral components. Analysis of lunar rock samples thought to have been derived from the original magma has given scientists a new estimate of the Moon's age.According to this theory for lunar formation, a rock type called ferroan anorthosite, or FAN, is the oldest of the Moon's crustal rocks, but scientists have had difficulty dating FAN samples. The research team used newly refined techniques to determine the age of a sample of FAN from the lunar rock that was brought back to Earth by the Apollo 16 mission in 1972.The team analyzed the isotopes of the elements lead and neodymium to place the FAN sample's age at 4.36 billion years. This figure is significantly younger than earlier estimates of the Moon's age that range as old as the age of the solar system at 4. 568 billion years. The new, younger age obtained for the oldest lunar crust is similar to ages obtained for the oldest terrestrial minerals -- zircons from western Australia -- suggesting that the oldest crusts on both Earth and Moon formed at approximately the same time, and that this time dates from shortly after the giant impact.This study is the first in which a single sample of FAN yielded consistent ages from multiple isotope dating techniques. This result strongly suggests that these ages pinpoint the time at which the sample crystallized."The extraordinarily young age of this lunar sample either means that the Moon solidified significantly later than previous estimates, or that we need to change our entire understanding of the Moon's geochemical history," Carnegie Institute of Science's geochemist and study author Richard Carlson said.

BEIJING, July 13 (Xinhuanet) -- Gasoline powers vehicles all around the world, but a sick Chinese man has been drinking the sticky liquid for 42 years under the illusion that it can relieve his physical pain.Chen Dejun, 71, lives by himself in shabby thatched cottage on a hill in Shuijiang township, Nanchuan district of southwest China's Chongqing municipality. The short and bony man said he drinks 3 to 3.5 kilograms of gasoline every month, which he buys from a station at the foot of the hill.Chen is known locally as a stonecutter and master of weaving bamboo with a good business sense. But he’s also known for his undying love of drinking gasoline.He developed the habit back in 1969 when he suddenly began coughing and felt pain in his chest. Seeing no progress after trying some medicine, he took up the folk remedy of drinking kerosene, Chongqing Evening News reported.It turned out to be helpful for him after the first sip, and he since became addicted to kerosene. Then he moved on to gasoline.Chen said it is hard to calculate exactly how much gasoline he has swallowed throughout his life, but the newspaper reported Chen has consumed an estimated 1.5 tons over the past 42 years.Chen's wife Yuan Huibi and their three sons tried many times to stop Chen's addiction to gasoline, but those efforts only made the family relations tense. Eight years ago Chen moved to the cottage to live alone.Sources from Honglou Hospital in Chongqing said Chen‘s health is fine despite having symptoms of emphysema. Chen refused to receive free check ups from the hospital.Feng Fu, an associate professor with the Second Hospital Affiliated to Chongqing Medical University, said Chen may have developed some resistance to gasoline. Otherwise, Feng said, it would be impossible for Chen to live. Feng also said gasoline may only work as anaesthetic for Chen but can’t cure his pain.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

SINGAPORE, Sept. 7 (Xinhua) -- Singapore scientists have found possible new ways to treat a type of aggressive breast cancer that is unresponsive to current forms of treatment, local broadcaster Channel NewsAsia reported on Wednesday.The team of scientists at the Genome Institute of Singapore ( GIS) and National University of Singapore (NUS), led by GIS senior group leader Qiang Yu, found that the enzyme EZH2 acts by inhibiting genes that stop the growth of tumors in the body.The insights could open the door to developing more effective treatment for fast spreading breast cancers, especially the estrogen receptor-negative breast cancer that is common all over the world.It was also found that through EZH2, cancer is promoted in the body by activating specific genes that impact breast cancer progression and cancer stem cell self-renewal.Yu said the new understanding on how EZH2 works as a cancer- causing gene in breast cancer has important therapeutic implication."The results suggest that small molecule drugs that block enzyme activity of EZH2 may not work for cancers caused by EZH2's activation genes," Yu said.Currently pharmaceutical companies have been developing drugs only to the block EZH2 enzyme activity so that tumor suppressers can perform their protective role in blocking cancer growth.Researchers said the next step would be to develop biomarkers to identify tumors with EZH2.This step would enable better treatment methods, with one of options being the development of therapies that shut down EZH2 completely and not just inhibit its enzymatic function.The findings have been published on the journal Molecular Cell.

来源：资阳报